News
Information, updates and press releases issued by Collaborations Pharmaceuticals.
Collaborations Pharmaceuticals, Inc. Introduce Batten Disease CLN1 Registry In Order to Find Patients
Collaborations Pharmaceuticals, Inc. has developed a registry for Batten Disease CLN1 In order to find patients with this rare disease and gather information.
Collaboration Leads to Repurposing an Existing Drug to Treat VX Poisoning
Collaborations Pharmaceuticals and Battelle published a new paper which demonstrated that an FDA approved drug may help in VX poisoning.
Collaborations Pharmaceuticals, Inc. Awarded A new $3.9M SBIR Commercialization Readiness Pilot Grant For Batten Disease
The National Institute of Neurological Disorders and Stroke has awarded a $3,953,139 SBIR grant to Collaborations Pharmaceuticals, Inc. for a Rare Disease
Can-Fite To Harness Artificial Intelligence To Develop Novel Anti-Cancer Drugs
Can-Fite signed an agreement with Collaborations Pharmaceuticals, a leading expert in Artificial Intelligence and Machine Learning
Collaborations Pharmaceuticals And UTMB Awarded A $295,000 Grant For Preclinical Development Of A Nipah Virus Treatment
RALEIGH, NORTH CAROLINA, USA, September 20, 2023/EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) and the Texas Medical Branch (UTMB) are pleased to announce that they were awarded a $295,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), to perform preclinical in vivo studies on a recently identified Nipah virus (NiV) inhibitor.